Clinical Trial: Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer

Study Status: Terminated
Recruit Status: Terminated
Study Type: Observational

Official Title: The Role of TAB3 Protein in Tumorigenesis

Brief Summary:

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is evaluating a tumor marker for testicular cancer, skin cancer, small intestine cancer, and pancreatic cancer.


Detailed Summary:

OBJECTIVES:

  • To identify TAB3 transcript/protein as a molecular marker of cancer, specifically testicular, skin, small intestine, and pancreatic cancer.
  • To characterize TAB3 and its signaling networks that are involved in tumorigenesis.

OUTLINE: Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.


Sponsor: Case Comprehensive Cancer Center

Current Primary Outcome:

  • Identification of TAB3 transcript/protein as a molecular marker of cancer [ Time Frame: end of study ]
  • Characterization of TAB3 and its signaling networks that are involved in tumorigenesis [ Time Frame: end of study ]


Original Primary Outcome:

  • Identification of TAB3 transcript/protein as a molecular marker of cancer
  • Characterization of TAB3 and its signaling networks that are involved in tumorigenesis


Current Secondary Outcome:

Original Secondary Outcome:

Information By: Case Comprehensive Cancer Center

Dates:
Date Received: May 9, 2009
Date Started: February 2007
Date Completion:
Last Updated: September 28, 2015
Last Verified: September 2015